Epclusa steps closer to potentially being declared as cost effective by NICE

Gilead’s pan-genotypic treatment Epclusa, which is a combination of sofosbuvir and velpatasvir has taken a step forward through The National Institute for Health and Care Excellence (NICE) approval process. NICE have published an appraisal consultation which indicates that the treatment may be approved as cost effective.

There are many more hurdles for it to cross before it could be made available within the NHS.